Hepcidin as an emerging predictor biomarker of leptomeningeal metastases in patients with metastatic breast cancer

Abstract Background Leptomeningeal metastatic disease (LMD) occurs in 5–19% of solid tumor cases, with breast cancer being a leading cause. Limited penetration of therapeutic agents into the CNS and increased patient survival may contribute to the rising incidence. Diagnosis relies on cerebrospinal...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Constance Delaby, Anas Al Herk, Christophe Hirtz, William Jacot, Maryline Laigre, Stéphane Pouderoux, Nicolas Pradeilles, Sylvain Lehmann, Amélie Darlix
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-11-01
coleção:	BMC Cancer
Assuntos:	Leptomeningeal metastases Fluid Biomarkers Diagnosis
Acesso em linha:	https://doi.org/10.1186/s12885-025-15124-6
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!